De Laere, Bram http://orcid.org/0000-0002-1174-0384
Crippa, Alessio http://orcid.org/0000-0002-2254-2420
Discacciati, Andrea
Larsson, Berit
Persson, Maria
Johansson, Susanne
D’hondt, Sanne http://orcid.org/0000-0002-7604-3117
Bergström, Rebecka http://orcid.org/0000-0001-7609-0733
Chellappa, Venkatesh
Mayrhofer, Markus
Banijamali, Mahsan
Kotsalaynen, Anastasijia
Schelstraete, Céline
Vanwelkenhuyzen, Jan Pieter http://orcid.org/0000-0001-6180-1889
Hjälm-Eriksson, Marie
Pettersson, Linn
Ullén, Anders
Lumen, Nicolaas
Enblad, Gunilla http://orcid.org/0000-0002-0594-724X
Thellenberg Karlsson, Camilla http://orcid.org/0000-0002-7061-7255
Jänes, Elin
Sandzén, Johan http://orcid.org/0009-0005-8044-3817
Schatteman, Peter
Nyre Vigmostad, Maria http://orcid.org/0009-0008-8574-686X
Olsson, Martha
Ghysel, Christophe
Sautois, Brieuc http://orcid.org/0000-0002-0029-7735
De Roock, Wendy
Van Bruwaene, Siska
Anden, Mats
Verbiene, Ingrida
De Maeseneer, Daan http://orcid.org/0000-0002-0339-5621
Everaert, Els
Darras, Jochen
Aksnessether, Bjørg Y.
Luyten, Daisy
Strijbos, Michiel
Mortezavi, Ashkan
Oldenburg, Jan
Ost, Piet
Eklund, Martin http://orcid.org/0000-0001-5032-5266
Grönberg, Henrik http://orcid.org/0000-0002-1073-2753
Lindberg, Johan
Funding for this research was provided by:
Vlaamse Liga Tegen Kanker (STI.VLK.2020.0006.01, STI.VLK.2022.0005.01, STI.VLK.2022.0005.01)
Krebsliga Beider Basel (KLbB-5580-02-2022)
Cancerfonden (21 1610 P)
Vetenskapsrådet (2021-00331)
Article History
Received: 13 January 2024
Accepted: 19 July 2024
First Online: 20 August 2024
Change Date: 28 August 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-024-03268-0
Competing interests
: A.C., A.D., B.L., M.P., S.J., S.D., M.B., A.K., C.S., J.V.W., M.H.E., L.P., E.J., J.S., P.S., M.N.V., M.O., S.V.B., M.A., I.V., E.E., J.D., D.L., M.S. and J.O. declare no competing interests. The following authors declare having received honoraria (privately or to institution/employer) from the following companies: MSD/Merck (B.S. and G.E.); Janssen-Cilag (B.S., B.D.L., A.M., C.T.K. and J.L.); AstraZeneca (B.D.L., C.T.K. and J.L.); ESMO (B.D.L.); Astellas (B.Y.A.); Pfizer (B.Y.A., H.G. and J.L.); BMS (BY.A. and W.D.R.); Ipsen (B.Y.A.); Johnson & Johnson Innovative Medicine (W.D.R.); Gilead (G.E.); Roche (G.E.); Pierre Fabre (G.E.); and Amgen (C.T.K.). The following authors declare having performed consulting or advisory roles for the following companies: Astellas (BS., A.U., D.D.M. and H.G.); Janssen-Cilag (B.S., P.O., A.U., H.G. and D.D.M.); BMS (B.S.); MSD/Merck (B.S., A.U., D.D.M. and P.O.); Bayer (B.S., P.O., H.G., A.M. and D.D.M.); AAA (P.O.); Novartis (P.O.); Pierre Fabre (A.U.); Pfizer (A.U. and D.D.M.); Roche (A.U.); Gilead (G.E.); Elicera Therapeutics (G.E).; XNK Therapeutics AB (G.E.); Sprint Bioscience AB (G.E.); Accord (H.G.); and AstraZeneca (H.G., D.D.M. and J.L.). The following authors declare having received research grants or sponsoring of trials from the following companaies: Bayer (P.O,. A.U. and N.L.); Janssen-Cilag (H.G.); AstraZeneca (H.G.); Merck (A.U. and W.D.R.); Pierre Fabre (A.U.); Ipsen (W.D.R. and N.L.); Johnson & Johnson Innovative Medicine (W.D.R.); and Roche Diagnostics (D.D.M.). The following authors declare having an unpaid membership in a (non-)governmental organization or advocacy organization: COMPERMED (B.D.L.); PSA Vlaanderen vzw (B.D.L. and C.G.); Swiss Urology (A.M.); Swedish Cancer Society (G.E.); and EAU Guidelines Urethral Stricture Panel (N.L.). The following authors declare having stock ownership or board membership: A3P AB (H.G. and M.E.); ClinSight AB (M.E.); Lighthouse Precision Oncology AB (B.D.L., J.L., M.M., R.B. and V.C.). The following authors declare having patents: J.L. and M.M. have filed a Swedish Patent Application (no. 2350786-6), ‘Method of identifying and adjusting for systematic variability in DNA abundance measurements’, which is applied in the current study to identify copy number alterations. However, the method will be made freely available under a GPL 3.0 license ().